Oct 23 2024 10 mins 8
Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).
Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).
